Interestingly, CCA cells expressing mutant KRAS were more sensitive to pharmacological PHGDH inhibition than those harboring the wild type allele, a situation that may open new therapeutic avenues for KRAS mutant CCAs. The gene discussed is PHGDH; the disease is cholangiocarcinoma.